Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen.(Aminobenzamidino) succinyl (ABAS) series of orally …

…, TE Rogers, K Williams, LA Schretzman…

Index: Zablocki; Rico; Garland; Rogers; Williams; Schretzman; Rao; Bovy; Tjoeng; Lindmark; Toth; Zupec; McMackins; Adams; Miyano; Markos; Milton; Paulson; Herin; et al. Journal of Medicinal Chemistry, 1995 , vol. 38, # 13 p. 2378 - 2394

Full Text: HTML

Citation Number: 125

Abstract

Our initial orally active fibrinogen receptor antagonist benzamidinopentanoyl (BAP) series which was discovered through truncation of our iv antiplatelet agent (SC-52012) demonstrated modest oral activity in canine studies (ethyl [5-(4-amidinophenyl) pentanoyll-3- amino-3-(3-pyridyl) propionate, le). Introduction of an amide bond adjacent to the benzamidine led to a novel series with an (aminobenzamidino) succinyl (ABAS) Arg-Gly ...